Auxilium reports three year data from XIAFLEX CORDLESS study in Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced three year recurrence data from the Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX® (collagenase clostridium histolyticum) in the treatment of adult Dupuytren's contracture patients with a palpable cord. This five year observational study was designed to assess the durability of response following treatment with XIAFLEX, as well as long-term safety and progression of disease in patients from earlier Auxilium studies. At three years, the nominal recurrence rate for the 623 joints previously treated successfully with XIAFLEX was 34.8%.

"In my opinion, the recurrence rate seen with XIAFLEX is comparable with or better than other minimally-invasive treatment options.  More importantly, the fingers I have treated with XIAFLEX do not appear to develop scar tissue, as opposed to surgically treated fingers. Scar slows recovery and complicates further treatment," said Dr. Tom Kaplan, of the Indiana Hand to Shoulder Center. "As a result, first-line use of XIAFLEX preserves all of my treatment options for those patients who do recur."


Auxilium Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
CuSTOM; Creating a healthier society by accelerating the translation of organoid technology